442 related articles for article (PubMed ID: 19251818)
41. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
Wang X; Zhang D; Xu W; Liu H; Wang W
Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
[TBL] [Abstract][Full Text] [Related]
43. In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences.
Mehrotra N; Lal J; Puri SK; Madhusudanan KP; Gupta RC
Biopharm Drug Dispos; 2007 Jul; 28(5):209-27. PubMed ID: 17410524
[TBL] [Abstract][Full Text] [Related]
44. Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans.
Zhu M; Whigan DB; Chang SY; Dockens RC
Drug Metab Dispos; 2008 Jan; 36(1):24-35. PubMed ID: 17908924
[TBL] [Abstract][Full Text] [Related]
45. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.
Kassahun K; Black WC; Nicoll-Griffith D; McIntosh I; Chauret N; Day S; Rosenberg E; Koeplinger K
Drug Metab Dispos; 2011 Jun; 39(6):1079-87. PubMed ID: 21422190
[TBL] [Abstract][Full Text] [Related]
47. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles.
Li CM; Lu Y; Narayanan R; Miller DD; Dalton JT
Drug Metab Dispos; 2010 Nov; 38(11):2032-9. PubMed ID: 20675405
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
Nakamura A; Hirota T; Sugihara K; Morino A
Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
[TBL] [Abstract][Full Text] [Related]
49. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
50. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
[TBL] [Abstract][Full Text] [Related]
51. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.
Dai GX; Tan W; Shen Y; Lin D; Xu RA; Lin Q; Wei Z
Toxicol Appl Pharmacol; 2024 May; 486():116934. PubMed ID: 38663673
[TBL] [Abstract][Full Text] [Related]
52. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
53. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
Choo EF; Driscoll JP; Feng J; Liederer B; Plise E; Randolph N; Shin Y; Wong S; Ran Y
Xenobiotica; 2009 Sep; 39(9):700-9. PubMed ID: 19552528
[TBL] [Abstract][Full Text] [Related]
54. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and pharmacodynamics of KR-66223, a novel DPP-4 inhibitor.
Song JS; Lee KR; Kwon HJ; Rhee SD; Kim MS; Choi SH; Lee SH; Song IS; Ahn JH; Ahn SH; Bae MA
Drug Metab Pharmacokinet; 2012; 27(2):216-22. PubMed ID: 22240842
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
Ye Q; Jiang M; Huang WT; Ling Y; Olson SH; Sun D; Xu G; Yan X; Wong BK; Jin L
Xenobiotica; 2015; 45(8):681-92. PubMed ID: 25798742
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).
Kim YB; Kopcho LM; Kirby MS; Hamann LG; Weigelt CA; Metzler WJ; Marcinkeviciene J
Arch Biochem Biophys; 2006 Jan; 445(1):9-18. PubMed ID: 16364232
[TBL] [Abstract][Full Text] [Related]
58. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Shubrook JH; Colucci RA; Schwartz FL
Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
[TBL] [Abstract][Full Text] [Related]
59. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
Perera MA; Yin D; Wu D; Chan KK; Miller DD; Dalton J
Drug Metab Dispos; 2006 Oct; 34(10):1713-21. PubMed ID: 16815963
[TBL] [Abstract][Full Text] [Related]
60. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
